Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trialJörge E. Cortes, Mark J. Levis, Neil P. Shah et al.|The Lancet Oncology|2018Cited by 268